Park Avenue Securities LLC Acquires Shares of 9,206 Smith & Nephew SNATS, Inc. (NYSE:SNN)

Park Avenue Securities LLC bought a new stake in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 9,206 shares of the medical equipment provider's stock, valued at approximately $261,000.

Several other hedge funds have also bought and sold shares of SNN. Van ECK Associates Corp increased its stake in Smith & Nephew SNATS by 111.2% in the 4th quarter. Van ECK Associates Corp now owns 9,240 shares of the medical equipment provider's stock worth $227,000 after buying an additional 4,865 shares in the last quarter. Principal Securities Inc. boosted its stake in shares of Smith & Nephew SNATS by 87.6% in the fourth quarter. Principal Securities Inc. now owns 1,480 shares of the medical equipment provider's stock worth $36,000 after acquiring an additional 691 shares during the period. Sanctuary Advisors LLC boosted its stake in shares of Smith & Nephew SNATS by 7.8% in the fourth quarter. Sanctuary Advisors LLC now owns 24,904 shares of the medical equipment provider's stock worth $639,000 after acquiring an additional 1,810 shares during the period. Hara Capital LLC raised its stake in Smith & Nephew SNATS by 391.4% during the 4th quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock valued at $60,000 after purchasing an additional 1,957 shares during the period. Finally, Lorne Steinberg Wealth Management Inc. lifted its holdings in Smith & Nephew SNATS by 0.9% in the 4th quarter. Lorne Steinberg Wealth Management Inc. now owns 233,155 shares of the medical equipment provider's stock worth $5,731,000 after purchasing an additional 2,160 shares in the last quarter. Institutional investors own 25.64% of the company's stock.

Smith & Nephew SNATS Price Performance

NYSE SNN traded down $0.71 on Tuesday, hitting $28.60. 1,310,615 shares of the stock were exchanged, compared to its average volume of 802,269. The company has a quick ratio of 1.33, a current ratio of 2.89 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS, Inc. has a 52-week low of $23.69 and a 52-week high of $31.72. The stock has a fifty day moving average price of $28.04 and a two-hundred day moving average price of $26.88.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on SNN shares. UBS Group lowered shares of Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a report on Wednesday, March 12th. Canaccord Genuity Group lifted their price target on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a report on Thursday, May 1st. HSBC downgraded shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Wall Street Zen upgraded shares of Smith & Nephew SNATS from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, February 26th. Finally, Hsbc Global Res lowered Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Six equities research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $28.00.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.